Investors organisations Eumedion and VEB have questioned the way Italian investment house Exor was able to build up a 15% stake in medical technology group Philips in one go, the Financieele Dagbad ...
Exor grew NAV per share despite sector headwinds, strengthened its cash position, and has a low leverage ratio. Lingotto delivered strong returns, recent IPOs and asset disposals enhanced flexibility, ...
Exor N.V. trades at a ~50% discount to NAV, offering indirect Ferrari exposure at a substantial valuation advantage. Exor’s diversified, complex portfolio and Agnelli family control drive persistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results